ID   OAS1_PIG                Reviewed;         349 AA.
AC   Q29599; O77734;
DT   15-DEC-1998, integrated into UniProtKB/Swiss-Prot.
DT   30-MAY-2000, sequence version 3.
DT   22-JUL-2015, entry version 88.
DE   RecName: Full=2'-5'-oligoadenylate synthase 1;
DE            Short=(2-5')oligo(A) synthase 1;
DE            Short=2-5A synthase 1;
DE            EC=2.7.7.84;
DE   AltName: Full=p42 OAS;
GN   Name=OAS1;
OS   Sus scrofa (Pig).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Laurasiatheria; Cetartiodactyla; Suina; Suidae;
OC   Sus.
OX   NCBI_TaxID=9823;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Small intestine;
RA   Hartmann R.;
RL   Thesis (1997), University of Aarhus, Denmark.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-128.
RC   TISSUE=Small intestine;
RX   PubMed=8672129; DOI=10.1007/s003359900153;
RA   Winteroe A.K., Fredholm M., Davies W.;
RT   "Evaluation and characterization of a porcine small intestine cDNA
RT   library: analysis of 839 clones.";
RL   Mamm. Genome 7:509-517(1996).
RN   [3]
RP   MUTAGENESIS OF LYS-65; ARG-209; TYR-230; GLU-233 AND ASP-300.
RX   PubMed=18604630; DOI=10.1007/s00018-008-8164-5;
RA   Torralba S., Sojat J., Hartmann R.;
RT   "2'-5' oligoadenylate synthetase shares active site architecture with
RT   the archaeal CCA-adding enzyme.";
RL   Cell. Mol. Life Sci. 65:2613-2620(2008).
RN   [4]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=20844035; DOI=10.1128/JVI.01003-10;
RA   Kristiansen H., Scherer C.A., McVean M., Iadonato S.P., Vends S.,
RA   Thavachelvam K., Steffensen T.B., Horan K.A., Kuri T., Weber F.,
RA   Paludan S.R., Hartmann R.;
RT   "Extracellular 2'-5' oligoadenylate synthetase stimulates RNase L-
RT   independent antiviral activity: a novel mechanism of virus-induced
RT   innate immunity.";
RL   J. Virol. 84:11898-11904(2010).
RN   [5]
RP   X-RAY CRYSTALLOGRAPHY (1.74 ANGSTROMS) OF 1-349, CATALYTIC ACTIVITY,
RP   SUBUNIT, METAL BINDING, AND MUTAGENESIS OF LYS-212.
RX   PubMed=14636576; DOI=10.1016/S1097-2765(03)00433-7;
RA   Hartmann R., Justesen J., Sarkar S.N., Sen G.C., Yee V.C.;
RT   "Crystal structure of the 2'-specific and double-stranded RNA-
RT   activated interferon-induced antiviral protein 2'-5'-oligoadenylate
RT   synthetase.";
RL   Mol. Cell 12:1173-1185(2003).
CC   -!- FUNCTION: Interferon-induced, dsRNA-activated antiviral enzyme
CC       which plays a critical role in cellular innate antiviral response.
CC       In addition, it may also play a role in other cellular processes
CC       such as apoptosis, cell growth, differentiation and gene
CC       regulation. Synthesizes higher oligomers of 2'-5'-oligoadenylates
CC       (2-5A) from ATP which then bind to the inactive monomeric form of
CC       ribonuclease L (RNase L) leading to its dimerization and
CC       subsequent activation. Activation of RNase L leads to degradation
CC       of cellular as well as viral RNA, resulting in the inhibition of
CC       protein synthesis, thus terminating viral replication. Can mediate
CC       the antiviral effect via the classical RNase L-dependent pathway
CC       or an alternative antiviral pathway independent of RNase L. The
CC       secreted form displays antiviral effect against vesicular
CC       stomatitis virus (VSV), herpes simplex virus type 2 (HSV-2), and
CC       encephalomyocarditis virus (EMCV) and stimulates the alternative
CC       antiviral pathway independent of RNase L.
CC       {ECO:0000269|PubMed:20844035}.
CC   -!- CATALYTIC ACTIVITY: 3 ATP = pppA2'p5'A2'p5'A + 2 diphosphate.
CC       {ECO:0000269|PubMed:14636576}.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC   -!- ENZYME REGULATION: Produced as a latent enzyme which is activated
CC       by dsRNA generated during the course of viral infection. The dsRNA
CC       activator must be at least 15 nucleotides long, and no
CC       modification of the 2'-hydroxyl group is tolerated. ssRNA or dsDNA
CC       do not act as activators (By similarity). {ECO:0000250}.
CC   -!- SUBUNIT: Monomer. Homotetramer (By similarity). {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Mitochondrion
CC       {ECO:0000250}. Nucleus {ECO:0000250}. Microsome {ECO:0000250}.
CC       Endoplasmic reticulum {ECO:0000250}. Secreted
CC       {ECO:0000269|PubMed:20844035}. Note=Associated with different
CC       subcellular fractions such as mitochondrial, nuclear, and
CC       rough/smooth microsomal fractions. {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the 2-5A synthase family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAA23153.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AJ225090; CAA12397.1; -; mRNA.
DR   EMBL; F14610; CAA23153.1; ALT_INIT; mRNA.
DR   RefSeq; NP_999468.1; NM_214303.1.
DR   UniGene; Ssc.1031; -.
DR   PDB; 1PX5; X-ray; 1.74 A; A/B=1-349.
DR   PDB; 4RWN; X-ray; 2.00 A; A=1-349.
DR   PDB; 4RWO; X-ray; 2.20 A; A=1-349.
DR   PDB; 4RWP; X-ray; 2.25 A; A=1-349.
DR   PDB; 4RWQ; X-ray; 3.10 A; A/B=1-349.
DR   PDBsum; 1PX5; -.
DR   PDBsum; 4RWN; -.
DR   PDBsum; 4RWO; -.
DR   PDBsum; 4RWP; -.
DR   PDBsum; 4RWQ; -.
DR   ProteinModelPortal; Q29599; -.
DR   SMR; Q29599; 1-349.
DR   PaxDb; Q29599; -.
DR   GeneID; 397570; -.
DR   KEGG; ssc:397570; -.
DR   CTD; 4938; -.
DR   eggNOG; NOG48070; -.
DR   HOVERGEN; HBG000994; -.
DR   InParanoid; Q29599; -.
DR   KO; K14216; -.
DR   BRENDA; 2.7.7.84; 6170.
DR   EvolutionaryTrace; Q29599; -.
DR   Proteomes; UP000008227; Unplaced.
DR   Genevisible; Q29599; SS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005783; C:endoplasmic reticulum; IEA:UniProtKB-SubCell.
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0005739; C:mitochondrion; IEA:UniProtKB-SubCell.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0001730; F:2'-5'-oligoadenylate synthetase activity; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0003725; F:double-stranded RNA binding; ISS:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0051607; P:defense response to virus; IDA:UniProtKB.
DR   GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW.
DR   GO; GO:0045071; P:negative regulation of viral genome replication; IDA:UniProtKB.
DR   GO; GO:0006164; P:purine nucleotide biosynthetic process; IDA:UniProtKB.
DR   Gene3D; 1.10.1410.20; -; 1.
DR   InterPro; IPR006117; 2-5-oligoadenylate_synth_CS.
DR   InterPro; IPR006116; 2-5-oligoadenylate_synth_N.
DR   InterPro; IPR018952; 2-5-oligoAdlate_synth_1_dom2/C.
DR   InterPro; IPR026774; 2-5A_synthase.
DR   InterPro; IPR002934; Nucleotidyltransferase.
DR   PANTHER; PTHR11258; PTHR11258; 1.
DR   Pfam; PF01909; NTP_transf_2; 1.
DR   Pfam; PF10421; OAS1_C; 1.
DR   PROSITE; PS00832; 25A_SYNTH_1; 1.
DR   PROSITE; PS00833; 25A_SYNTH_2; 1.
DR   PROSITE; PS50152; 25A_SYNTH_3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Antiviral defense; ATP-binding; Complete proteome;
KW   Cytoplasm; Endoplasmic reticulum; Immunity; Innate immunity;
KW   Magnesium; Metal-binding; Microsome; Mitochondrion;
KW   Nucleotide-binding; Nucleotidyltransferase; Nucleus;
KW   Reference proteome; RNA-binding; Secreted; Transferase.
FT   CHAIN         1    349       2'-5'-oligoadenylate synthase 1.
FT                                /FTId=PRO_0000160262.
FT   REGION       12     59       Interaction with dsRNA. {ECO:0000250}.
FT   REGION      199    209       Interaction with dsRNA. {ECO:0000250}.
FT   METAL        74     74       Magnesium; catalytic. {ECO:0000250}.
FT   METAL        76     76       Magnesium; catalytic. {ECO:0000250}.
FT   METAL       147    147       Magnesium; catalytic. {ECO:0000250}.
FT   BINDING      62     62       ATP. {ECO:0000250}.
FT   BINDING     212    212       ATP.
FT   BINDING     229    229       ATP. {ECO:0000250}.
FT   SITE        157    157       Interaction with dsRNA. {ECO:0000250}.
FT   MUTAGEN      65     65       K->A: Significant loss of activity.
FT                                {ECO:0000269|PubMed:18604630}.
FT   MUTAGEN     209    209       R->A: Significant loss of activity.
FT                                {ECO:0000269|PubMed:18604630}.
FT   MUTAGEN     212    212       K->A: Significant loss of activity.
FT                                {ECO:0000269|PubMed:14636576}.
FT   MUTAGEN     230    230       Y->A: Significant loss of activity.
FT                                {ECO:0000269|PubMed:18604630}.
FT   MUTAGEN     233    233       E->A: Significant loss of activity.
FT                                {ECO:0000269|PubMed:18604630}.
FT   MUTAGEN     300    300       D->A: Significant loss of activity.
FT                                {ECO:0000269|PubMed:18604630}.
FT   CONFLICT     54     54       V -> F (in Ref. 2; CAA23153).
FT                                {ECO:0000305}.
FT   CONFLICT    122    122       S -> R (in Ref. 2; CAA23153).
FT                                {ECO:0000305}.
FT   HELIX         3      5       {ECO:0000244|PDB:1PX5}.
FT   HELIX         8     10       {ECO:0000244|PDB:1PX5}.
FT   HELIX        11     18       {ECO:0000244|PDB:1PX5}.
FT   HELIX        23     43       {ECO:0000244|PDB:1PX5}.
FT   STRAND       53     62       {ECO:0000244|PDB:1PX5}.
FT   STRAND       73     83       {ECO:0000244|PDB:1PX5}.
FT   HELIX        89     92       {ECO:0000244|PDB:1PX5}.
FT   HELIX        94    111       {ECO:0000244|PDB:1PX5}.
FT   STRAND      115    120       {ECO:0000244|PDB:1PX5}.
FT   STRAND      132    136       {ECO:0000244|PDB:1PX5}.
FT   TURN        138    140       {ECO:0000244|PDB:1PX5}.
FT   STRAND      143    152       {ECO:0000244|PDB:1PX5}.
FT   HELIX       166    179       {ECO:0000244|PDB:1PX5}.
FT   TURN        182    185       {ECO:0000244|PDB:1PX5}.
FT   HELIX       186    189       {ECO:0000244|PDB:1PX5}.
FT   HELIX       190    198       {ECO:0000244|PDB:1PX5}.
FT   HELIX       202    219       {ECO:0000244|PDB:1PX5}.
FT   HELIX       229    243       {ECO:0000244|PDB:1PX5}.
FT   HELIX       251    263       {ECO:0000244|PDB:1PX5}.
FT   HELIX       264    267       {ECO:0000244|PDB:1PX5}.
FT   STRAND      278    280       {ECO:0000244|PDB:1PX5}.
FT   HELIX       281    291       {ECO:0000244|PDB:1PX5}.
FT   STRAND      293    295       {ECO:0000244|PDB:1PX5}.
FT   STRAND      297    299       {ECO:0000244|PDB:1PX5}.
FT   HELIX       313    326       {ECO:0000244|PDB:1PX5}.
FT   HELIX       330    332       {ECO:0000244|PDB:1PX5}.
SQ   SEQUENCE   349 AA;  40246 MW;  06949A35BFCF7710 CRC64;
     MELRHTPARD LDKFIEDHLL PNTCFRTQVK EAIDIVCRFL KERCFQGTAD PVRVSKVVKG
     GSSGKGTTLR GRSDADLVVF LTKLTSFEDQ LRRRGEFIQE IRRQLEACQR EQKFKVTFEV
     QSPRRENPRA LSFVLSSPQL QQEVEFDVLP AFDALGQWTP GYKPNPEIYV QLIKECKSRG
     KEGEFSTCFT ELQRDFLRNR PTKLKSLIRL VKHWYQTCKK THGNKLPPQY ALELLTVYAW
     EQGSRKTDFS TAQGFQTVLE LVLKHQKLCI FWEAYYDFTN PVVGRCMLQQ LKKPRPVILD
     PADPTGNVGG GDTHSWQRLA QEARVWLGYP CCKNLDGSLV GAWTMLQKI
//
